Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.

Sharma S, Jafari M, Bangar A, William K, Guatelli J, Lewinski MK.

J Virol. 2019 May 15;93(11). pii: e02315-18. doi: 10.1128/JVI.02315-18. Print 2019 Jun 1.

PMID:
30867310
2.

An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.

Sharma S, Lewinski MK, Guatelli J.

J Virol. 2018 Oct 29;92(22). pii: e00753-18. doi: 10.1128/JVI.00753-18. Print 2018 Nov 15.

3.

Phosphoserine acidic cluster motifs bind distinct basic regions on the μ subunits of clathrin adaptor protein complexes.

Singh R, Stoneham C, Lim C, Jia X, Guenaga J, Wyatt R, Wertheim JO, Xiong Y, Guatelli J.

J Biol Chem. 2018 Oct 5;293(40):15678-15690. doi: 10.1074/jbc.RA118.003080. Epub 2018 Aug 22.

PMID:
30135209
4.

Cooperation of the Ebola Virus Proteins VP40 and GP1,2 with BST2 To Activate NF-κB Independently of Virus-Like Particle Trapping.

Rizk MG, Basler CF, Guatelli J.

J Virol. 2017 Oct 27;91(22). pii: e01308-17. doi: 10.1128/JVI.01308-17. Print 2017 Nov 15.

5.

Quantitative Temporal Viromics of an Inducible HIV-1 Model Yields Insight to Global Host Targets and Phospho-Dynamics Associated with Protein Vpr.

Lapek JD Jr, Lewinski MK, Wozniak JM, Guatelli J, Gonzalez DJ.

Mol Cell Proteomics. 2017 Aug;16(8):1447-1461. doi: 10.1074/mcp.M116.066019. Epub 2017 Jun 12.

6.

Endocytic activity of HIV-1 Vpu: Phosphoserine-dependent interactions with clathrin adaptors.

Stoneham CA, Singh R, Jia X, Xiong Y, Guatelli J.

Traffic. 2017 Aug;18(8):545-561. doi: 10.1111/tra.12495. Epub 2017 Jun 27.

7.

The Evolutionary Histories of Antiretroviral Proteins SERINC3 and SERINC5 Do Not Support an Evolutionary Arms Race in Primates.

Murrell B, Vollbrecht T, Guatelli J, Wertheim JO.

J Virol. 2016 Aug 26;90(18):8085-9. doi: 10.1128/JVI.00972-16. Print 2016 Sep 15.

8.

Non-degradative Ubiquitination of Protein Kinases.

Ball KA, Johnson JR, Lewinski MK, Guatelli J, Verschueren E, Krogan NJ, Jacobson MP.

PLoS Comput Biol. 2016 Jun 2;12(6):e1004898. doi: 10.1371/journal.pcbi.1004898. eCollection 2016 Jun.

9.

Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1.

Tokarev A, Stoneham C, Lewinski MK, Mukim A, Deshmukh S, Vollbrecht T, Spina CA, Guatelli J.

J Virol. 2015 Dec 16;90(5):2486-502. doi: 10.1128/JVI.02736-15.

10.

Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly.

Lewinski MK, Jafari M, Zhang H, Opella SJ, Guatelli J.

J Biol Chem. 2015 Apr 24;290(17):10919-33. doi: 10.1074/jbc.M114.630095. Epub 2015 Mar 10.

11.

Long-term persistence of zoster vaccine efficacy.

Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN; Shingles Prevention Study Group.

Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918. Epub 2014 Nov 20.

12.

Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.

Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, Guatelli J, Xiong Y.

Elife. 2014 Apr 29;3:e02362. doi: 10.7554/eLife.02362.

13.

Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Jafari M, Guatelli J, Lewinski MK.

J Virol. 2014 May;88(9):5062-78. doi: 10.1128/JVI.03472-13. Epub 2014 Feb 26.

14.

Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.

Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel-D, Rauch A, Ledergerber B, Deeks SG, Günthard HF, Wong JK, Pillai SK.

J Virol. 2014 Jan;88(1):763-7. doi: 10.1128/JVI.02687-13. Epub 2013 Oct 23.

15.

HIV latency and integration site placement in five cell-based models.

Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, Berry CC, Looney D, Shan L, Agosto LM, Pace MJ, Siliciano RF, O'Doherty U, Guatelli J, Planelles V, Bushman FD.

Retrovirology. 2013 Aug 16;10:90. doi: 10.1186/1742-4690-10-90.

16.

Safety of zoster vaccine in elderly adults following documented herpes zoster.

Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group.

J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30.

17.

Stimulation of NF-κB activity by the HIV restriction factor BST2.

Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J.

J Virol. 2013 Feb;87(4):2046-57. doi: 10.1128/JVI.02272-12. Epub 2012 Dec 5.

18.

Interferon-induced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu.

Miyakawa K, Sawasaki T, Matsunaga S, Tokarev A, Quinn G, Kimura H, Nomaguchi M, Adachi A, Yamamoto N, Guatelli J, Ryo A.

Sci Signal. 2012 Oct 9;5(245):ra73. doi: 10.1126/scisignal.2003212.

19.

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; Shingles Prevention Study Group.

Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638. Epub 2012 Jul 24.

20.

Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef.

Jia X, Singh R, Homann S, Yang H, Guatelli J, Xiong Y.

Nat Struct Mol Biol. 2012 Jun 17;19(7):701-6. doi: 10.1038/nsmb.2328.

21.

Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK; Swiss HIV Cohort Study.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3035-40. doi: 10.1073/pnas.1111573109. Epub 2012 Feb 6.

22.

HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions.

Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J.

J Biol Chem. 2012 Jan 2;287(1):58-67. doi: 10.1074/jbc.M111.296772. Epub 2011 Nov 9.

23.
24.

Upregulation of BST-2/Tetherin by HIV infection in vivo.

Homann S, Smith D, Little S, Richman D, Guatelli J.

J Virol. 2011 Oct;85(20):10659-68. doi: 10.1128/JVI.05524-11. Epub 2011 Aug 17.

25.

Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.

Lau D, Kwan W, Guatelli J.

J Virol. 2011 Oct;85(19):9834-46. doi: 10.1128/JVI.02633-10. Epub 2011 Aug 3.

26.

BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action.

Skasko M, Tokarev A, Chen CC, Fischer WB, Pillai SK, Guatelli J.

Virology. 2011 Mar 1;411(1):65-77. doi: 10.1016/j.virol.2010.12.038. Epub 2011 Jan 14.

27.

Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.

Tokarev AA, Munguia J, Guatelli JC.

J Virol. 2011 Jan;85(1):51-63. doi: 10.1128/JVI.01795-10. Epub 2010 Oct 27.

28.

BST-2 mediated restriction of simian-human immunodeficiency virus.

Ruiz A, Lau D, Mitchell RS, Hill MS, Schmitt K, Guatelli JC, Stephens EB.

Virology. 2010 Oct 25;406(2):312-21. doi: 10.1016/j.virol.2010.07.021. Epub 2010 Aug 13.

29.

BST-2/tetherin: a new component of the innate immune response to enveloped viruses.

Evans DT, Serra-Moreno R, Singh RK, Guatelli JC.

Trends Microbiol. 2010 Sep;18(9):388-96. doi: 10.1016/j.tim.2010.06.010. Epub 2010 Aug 3. Review.

30.

Tetherin restricts productive HIV-1 cell-to-cell transmission.

Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin AG, Guatelli J, Schwartz O.

PLoS Pathog. 2010 Jun 17;6(6):e1000955. doi: 10.1371/journal.ppat.1000955.

31.

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM.

Retrovirology. 2010 Jun 7;7:51. doi: 10.1186/1742-4690-7-51. Erratum in: Retrovirology. 2011;8:85.

32.

Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.

Fitzpatrick K, Skasko M, Deerinck TJ, Crum J, Ellisman MH, Guatelli J.

PLoS Pathog. 2010 Mar 5;6(3):e1000701. doi: 10.1371/journal.ppat.1000701.

33.

The Vpu protein: new concepts in virus release and CD4 down-modulation.

Ruiz A, Guatelli JC, Stephens EB.

Curr HIV Res. 2010 Apr;8(3):240-52. Review.

34.

How innate immunity can inhibit the release of HIV-1 from infected cells.

Guatelli J.

N Engl J Med. 2010 Feb 11;362(6):553-4. doi: 10.1056/NEJMcibr0911557. No abstract available.

PMID:
20147723
35.

An MHC-I cytoplasmic domain/HIV-1 Nef fusion protein binds directly to the mu subunit of the AP-1 endosomal coat complex.

Singh RK, Lau D, Noviello CM, Ghosh P, Guatelli JC.

PLoS One. 2009 Dec 18;4(12):e8364. doi: 10.1371/journal.pone.0008364.

36.

BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction.

Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, Yamamoto N.

PLoS Pathog. 2009 Dec;5(12):e1000700. doi: 10.1371/journal.ppat.1000700. Epub 2009 Dec 18.

37.

Interactions of viral protein U (Vpu) with cellular factors.

Guatelli JC.

Curr Top Microbiol Immunol. 2009;339:27-45. doi: 10.1007/978-3-642-02175-6_2. Review.

PMID:
20012522
38.

Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.

Tokarev A, Skasko M, Fitzpatrick K, Guatelli J.

AIDS Res Hum Retroviruses. 2009 Dec;25(12):1197-210. doi: 10.1089/aid.2009.0253. Review.

39.

Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.

Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC.

PLoS Pathog. 2009 May;5(5):e1000450. doi: 10.1371/journal.ppat.1000450. Epub 2009 May 29.

40.

Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.

Ruiz A, Hill MS, Schmitt K, Guatelli J, Stephens EB.

Virology. 2008 Aug 15;378(1):58-68. doi: 10.1016/j.virol.2008.05.022. Epub 2008 Jun 24.

41.

Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 Nef.

Mitchell RS, Chaudhuri R, Lindwasser OW, Tanaka KA, Lau D, Murillo R, Bonifacino JS, Guatelli JC.

J Virol. 2008 Aug;82(16):7758-67. doi: 10.1128/JVI.02668-07. Epub 2008 Jun 4.

42.

The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J.

Cell Host Microbe. 2008 Apr 17;3(4):245-52. doi: 10.1016/j.chom.2008.03.001. Epub 2008 Mar 13.

43.

HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes.

Van Damme N, Guatelli J.

Cell Microbiol. 2008 May;10(5):1040-57. Epub 2007 Dec 10.

PMID:
18076669
45.

Maintenance of Nef-mediated modulation of major histocompatibility complex class I and CD4 after sexual transmission of human immunodeficiency virus type 1.

Noviello CM, Pond SL, Lewis MJ, Richman DD, Pillai SK, Yang OO, Little SJ, Smith DM, Guatelli JC.

J Virol. 2007 May;81(9):4776-86. Epub 2007 Feb 28.

46.
47.

Dynamic interaction of HIV-1 Nef with the clathrin-mediated endocytic pathway at the plasma membrane.

Burtey A, Rappoport JZ, Bouchet J, Basmaciogullari S, Guatelli J, Simon SM, Benichou S, Benmerah A.

Traffic. 2007 Jan;8(1):61-76. Epub 2006 Nov 28.

48.
49.

A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay.

Day JR, Martínez LE, Sásik R, Hitchin DL, Dueck ME, Richman DD, Guatelli JC.

J Virol Methods. 2006 Oct;137(1):125-33. Epub 2006 Jul 28.

PMID:
16876264
50.

Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif.

Coleman SH, Madrid R, Van Damme N, Mitchell RS, Bouchet J, Servant C, Pillai S, Benichou S, Guatelli JC.

J Virol. 2006 Feb;80(4):1837-49.

Supplemental Content

Loading ...
Support Center